

## Alberta RSV Prevention Program

### Criteria for the use of Palivizumab 2020-2021

1. Premature: less than or equal to **28 6/7 weeks gestational age** born after May 31, 2020
2. Premature: **29 0/7 - 32 6/7 weeks gestational age** born after September 30, 2020
3. Premature: **33 0/7 - 35 6/7 weeks gestational age** and born after October 31, 2020  
*Please check all applicable risk factors below:*
  - Is the birth month in November, December, January or February?
  - Small (less than 10<sup>th</sup> percentile) for gestational age?
  - Is gender male?
  - Is the child or preschool sibling less than or equal to 4 years of age attending daycare greater than or equal to 3 “half “days per week?
  - Are there more than 5 individuals in the home counting the child?
  - Is there more than one smoker in the household?
  - Does the family live more than 2 hours from the nearest hospital that provides bronchiolitis treatment?
  - Does family live in a remote location with no permanent road access (i.e. Fox Lake)
4. Premature: **33 0/7 - 35 6/7 weeks gestational age** otherwise healthy and a twin/triplet of a patient who qualifies for RSV immunoprophylaxis

*Point of emphasis: To be eligible for RSV immunoprophylaxis an algorithm score of greater than 55 is required. The Alberta RSV Prevention Program will calculate the algorithm score and determine eligibility on risk assessment forms with completed algorithms.*

5. Premature: Multiple birth (excluding twins) less than or equal to **35 6/7 weeks gestational age** born after September 30, 2020
6. Premature: less than or equal to **35 6/7 weeks gestational age and less than 2 years of age** as at December 01, 2020 with chronic lung disease as evidenced by: *(Check all applicable factors)*
  - home oxygen after May 31, 2020
  - on long term prophylaxis or a recent exacerbation needing systemic steroids **Details:**

*Point of emphasis: Please provide current oxygen supplement requirement- type and flow and concomitant medications*

7. Severe hemodynamically significant congenital heart disease: **age less than 2 years of age** as at December 01, 2020 **Provide specific diagnosis and/or cardiac medications:**

*Point of emphasis: A cardiologist will review referrals to determine if the congenital heart defect is hemodynamically significant. Examples of eligible and non-eligible cardiac lesions are listed below.*

Eligible	Non Eligible
<ul style="list-style-type: none"> <li>• pulmonary artery hypertension</li> <li>• Tetralogy of Fallot</li> <li>• hypoplastic left heart</li> <li>• cyanotic heart disease</li> <li>• congestive heart disease</li> <li>• atrio-ventricular septal defect</li> <li>• congenital heart disease in association with prematurity or CLD</li> </ul>	<ul style="list-style-type: none"> <li>• uncomplicated or small ASD and VSD</li> <li>• patent ductus arteriosus</li> <li>• pulmonary stenosis</li> <li>• uncomplicated aortic stenosis</li> <li>• mild coarctation of the aorta</li> </ul>

8. Tracheostomy: **age less than 2 years of age** as at December 01, 2020. Prophylaxis may be considered in those **age less than 4 years** as at December 01, 2020 if ventilator dependent
9. Cystic Fibrosis: prophylaxis may be considered in those born during the current season with the birth month of November, December, January or February
10. Trisomy 21: **age less than 1 year of age** as at December 01, 2020
11. Other categories in term or preterm infants: **age less than 2 years of age** as at December 01, 2020 including:
  - persistent requirement for home oxygen

- meconium aspiration or gastro-esophageal reflux disease with long term oxygen supplements
- congenital anomaly of airway i.e. trachea-esophageal fistula, congenital diaphragmatic hernia, Pierre Robin Sequence
- congenital anomaly of the lung i.e. congenital pulmonary airway malformation, interstitial lung disease
- significant immunodeficiency. **Exception with no age restriction:** severe combined immunodeficiency, stem cell transplant or bone marrow transplant first year post transplant.

*Point of Emphasis: In the event the SCT/BMT occurs during the RSV season i.e. January or February and the first year post transplant strides two RSV seasons. RSV immunoprophylaxis will be provided for the first season and second season at the request of the referring physician.*

- neuromuscular disorders. **Exception with no age restriction:** spinal muscular atrophy type 1 weighing less than 15 kg

- 12.** Other conditions not listed above, physician referral only. Please include supporting documentation. Requires approval from an Alberta RSV Prevention Medical Director

*Point of emphasis: Requirement for oxygen due to central apnea or obstructive sleep apnea are **not** indications for use of palivizumab*